BPX-603

N/A

Report date: 2023/04/21 20:00:22

Base Information

Drug NameBPX-603

Drug Alias NameBPX-603 GoCAR-TBPX-603

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBellicum Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBellicum Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A